466 related articles for article (PubMed ID: 33134567)
1. Kynurenine pathway in Parkinson's disease-An update.
Venkatesan D; Iyer M; Narayanasamy A; Siva K; Vellingiri B
eNeurologicalSci; 2020 Dec; 21():100270. PubMed ID: 33134567
[TBL] [Abstract][Full Text] [Related]
2. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Hajibeygi R; Shool S; Sodeifian F; Klegeris A; McElhinney A; Tavirani MR; Sayehmiri F
Front Immunol; 2022; 13():997240. PubMed ID: 36263032
[TBL] [Abstract][Full Text] [Related]
3. Involvement of the kynurenine pathway in human glioma pathophysiology.
Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ
PLoS One; 2014; 9(11):e112945. PubMed ID: 25415278
[TBL] [Abstract][Full Text] [Related]
4. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.
Myint AM; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():304-13. PubMed ID: 24184687
[TBL] [Abstract][Full Text] [Related]
5. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
6. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.
Bai MY; Lovejoy DB; Guillemin GJ; Kozak R; Stone TW; Koola MM
Complex Psychiatry; 2021 Aug; 7(1-2):19-33. PubMed ID: 35141700
[TBL] [Abstract][Full Text] [Related]
7. The kynurenine pathway in brain tumor pathogenesis.
Adams S; Braidy N; Bessede A; Brew BJ; Grant R; Teo C; Guillemin GJ
Cancer Res; 2012 Nov; 72(22):5649-57. PubMed ID: 23144293
[TBL] [Abstract][Full Text] [Related]
8. The Footprint of Kynurenine Pathway in Neurodegeneration: Janus-Faced Role in Parkinson's Disorder and Therapeutic Implications.
Behl T; Kaur I; Sehgal A; Singh S; Bhatia S; Al-Harrasi A; Zengin G; Bumbu AG; Andronie-Cioara FL; Nechifor AC; Gitea D; Bungau AF; Toma MM; Bungau SG
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201647
[TBL] [Abstract][Full Text] [Related]
9. Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Mohamadkhani A; Klegeris A; McElhinney A; Mafi Z; Hajiesmaeili M; Sayehmiri F
Front Immunol; 2022; 13():1013784. PubMed ID: 36426364
[TBL] [Abstract][Full Text] [Related]
10. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
Fujigaki H; Yamamoto Y; Saito K
Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
[TBL] [Abstract][Full Text] [Related]
11. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
Breda C; Sathyasaikumar KV; Sograte Idrissi S; Notarangelo FM; Estranero JG; Moore GG; Green EW; Kyriacou CP; Schwarcz R; Giorgini F
Proc Natl Acad Sci U S A; 2016 May; 113(19):5435-40. PubMed ID: 27114543
[TBL] [Abstract][Full Text] [Related]
12. Peripheral Tryptophan - Kynurenine Metabolism Associated with Metabolic Syndrome is Different in Parkinson's and Alzheimer's Diseases.
Oxenkrug G; van der Hart M; Roeser J; Summergrad P
Endocrinol Diabetes Metab J; 2017 Nov; 1(4):. PubMed ID: 29292800
[TBL] [Abstract][Full Text] [Related]
13. Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases.
Song P; Ramprasath T; Wang H; Zou MH
Cell Mol Life Sci; 2017 Aug; 74(16):2899-2916. PubMed ID: 28314892
[TBL] [Abstract][Full Text] [Related]
14. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
[TBL] [Abstract][Full Text] [Related]
15. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
[TBL] [Abstract][Full Text] [Related]
16. Effects of Kynurenine Pathway Metabolites on Intracellular NAD Synthesis and Cell Death in Human Primary Astrocytes and Neurons.
Braidy N; Grant R; Brew BJ; Adams S; Jayasena T; Guillemin GJ
Int J Tryptophan Res; 2009; 2():61-9. PubMed ID: 22084582
[TBL] [Abstract][Full Text] [Related]
17. Research progress on the kynurenine pathway in the prevention and treatment of Parkinson's disease.
Chen P; Geng X
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2225800. PubMed ID: 37381707
[TBL] [Abstract][Full Text] [Related]
18. Role of d-amino acid oxidase in the production of kynurenine pathway metabolites from d-tryptophan in mice.
Notarangelo FM; Wang XD; Horning KJ; Schwarcz R
J Neurochem; 2016 Feb; 136(4):804-814. PubMed ID: 26661897
[TBL] [Abstract][Full Text] [Related]
19. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases.
Lovelace MD; Varney B; Sundaram G; Lennon MJ; Lim CK; Jacobs K; Guillemin GJ; Brew BJ
Neuropharmacology; 2017 Jan; 112(Pt B):373-388. PubMed ID: 26995730
[TBL] [Abstract][Full Text] [Related]
20. The Mediating Role of Kynurenine Pathway Metabolites on the Relationship Between Inflammation and Muscle Mass in Oldest-Old Men.
Hetherington-Rauth M; Johnson E; Migliavacca E; Langsetmo L; Hepple RT; Ryan TE; Ferrucci L; Breuillé D; Corthesy J; Lane NE; Feige JN; Napoli N; Tramontana F; Orwoll ES; Cawthon PM
J Gerontol A Biol Sci Med Sci; 2024 Jul; 79(7):. PubMed ID: 38761087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
